• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    VBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate Update

    3/23/22 7:00:00 AM ET
    $VBLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VBLT alert in real time by email
    • OVAL top-line data for ofra-vec progression free survival (PFS) primary endpoint expected in 2H 2022; with positive results, VBL anticipates submitting a Biologics License Application (BLA) in 1H 2023



    • Completed patient enrollment in the 409 patient OVAL Phase 3 registration enabling trial investigating ofra-vec in patients with platinum-resistant ovarian cancer



    • Preliminary data from ofra-vec Phase 2 trials in mCRC and rGBM expected in 2022



    • VB-601, a monoclonal antibody targeting monocytes for prevalent and chronic inflammatory disorders, expected to enter the clinic in 2H 2022



    • KOL event in NYC to discuss ofra-vec in ovarian cancer planned for April 11, 2022



    • Conference Call and Webcast at 8:30 a.m. EDT Today

    TEL AVIV, Israel and NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) (VBL), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant and solid tumors and immune or inflammatory indications, today announced financial results for the fiscal year ended December 31, 2021, and provided a corporate update.

    "2021 was a year of excellent progress for VBL as we advanced our development programs, strengthened our management team and established a direct presence in the United States," said Dror Harats, M.D., Chief Executive Officer of VBL. "The company is positioned for a potentially transformational year in 2022 as we look forward to the PFS primary endpoint top-line data readout in the Phase 3 OVAL trial in the second half of 2022. We are also expecting preliminary data on ofra-vec from the Phase 2 trials in mCRC and rGBM and plan to enter the clinic in the second half of the year with VB-601, the first candidate from our novel anti-inflammatory program targeting monocytes. We are pleased with the progress and execution at VBL and see multiple opportunities to create value in 2022."

    Fourth Quarter and Recent Corporate Highlights

    Development Programs

    • Enrollment in the Phase 3 OVAL registration-enabling trial in recurrent platinum-resistant ovarian cancer has been completed, with a total of 409 patients enrolled globally.
    • The Independent Data Safety Monitoring Committee for the OVAL trial conducted a pre-planned safety review of the 370 patients randomized in the trial by December 31, 2021 and unanimously recommended that the trial continue as planned.
    • Ofra-vec Phase 2 clinical trials in recurrent glioblastoma multiforme (rGBM) and metastatic colorectal cancer (mCRC) continue as planned, with preliminary data expected in 2022.
    • IND-enabling toxicology studies have been successfully completed for VB-601, a monoclonal antibody targeting monocytes for prevalent and chronic inflammatory disorders, and demonstrated an acceptable toxicology profile to proceed into clinical development. VBL expects to initiate a first-in-human clinical trial for the program in the second half of 2022.

    Corporate

    • Strengthened the management team with the appointment of Matthew Trudeau to the newly created position of Chief Commercial Officer to further advance VBL's strategic plan to become a commercial organization, and Sam Backenroth as Chief Financial Officer.
    • Established operations in the United States.

    KOL Event on Ovarian Cancer, April 11

    • VBL plans to host an in-person Key Opinion Leader (KOL) luncheon for the investment community on Monday, April 11, in New York City. The event will feature presentations and a panel discussion with KOLs who will discuss the current treatment landscape and unmet medical need in treating patients with ovarian cancer. For more details and registration to the event refer to: https://ir.vblrx.com/events/event-details/kol-event-ovarian-cancer.

    Financial Results for the Full Year 2021

    • At December 31, 2021, VBL had cash, cash equivalents, short-term bank deposits and restricted bank deposits of $53.5 million. VBL expects that its cash, cash equivalents, short-term bank deposits, and restricted bank deposits will be sufficient to fund currently planned operating expenses and capital expenditures for at least twelve months from the date of the readout of top-line PFS data from the Phase 3 OVAL trial.

    • For the year ended December 31, 2021, VBL reported a net loss of $29.9 million, or ($0.45) per basic share, compared to a net loss of $24.2 million, or ($0.55) per basic share, in the comparable period in 2020.

    • Revenues for the year ended December 31, 2021, were $0.8 million, as compared to $0.9 million in the comparable period in 2020.

    • For the year ended December 31, 2021, total operating expenses were approximately $30.4 million, consisting of $22.7 million in research and development expenses, net, and $7.7 million in general and administrative expenses. This compares with total operating expenses of $25.1 million in the year ended December 31, 2020, which was comprised of $19.7 million in research and development expenses, net, and $5.4 million in general and administrative expenses.

    Conference Call and Webcast, Wednesday, March 23, 2022 at 8:30am ET

    Call Details

    Conference ID:13727878
    US:1-877-407-9208
    Israel Local:1-809-406-247
    International:1-201-493-6784
    Webcast:https://edge.media-server.com/mmc/p/6ntrdxh8

    The live webcast will be available online and may be accessed from the "Events and Presentations" page of VBL's website. A replay of the webcast will be available beginning approximately one hour after the conclusion of the call and will remain available for at least 30 days thereafter.

    About VBL Therapeutics

    Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for difficult-to-treat malignant solid tumors and immune or inflammatory indications. VBL's novel VTS™ gene-based platform and antibody-based monocyte targeting technology enable the creation of a pipeline of programs that are designed to harness the body's innate biological processes to provide unique solutions for significant unmet medical needs. VBL's lead oncology product candidate, ofranergene obadenovec (`ofra-vec`, or VB-111), is an investigational targeted anti-cancer gene-based agent in development to treat a wide range of solid tumors. Ofra-vec is currently being studied in a Phase 3 registration-enabling clinical trial (NCT03398655) for platinum-resistant ovarian cancer. To learn more about VBL, please visit vblrx.com or follow VBL on LinkedIn, Twitter, YouTube or Facebook.

    Forward Looking Statements

    This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. These forward-looking statements include, but are not limited to, statements regarding timing of topline data from the OVAL trial and its potential to support BLA submission, the therapeutic benefit of ofra-vec (VB-111) and its ability to obtain regulatory approval, among others. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with the development of pharmaceutical product candidates, including risks associated with conducting research and development, clinical trials and related regulatory reviews and approvals, the risk that historical clinical trial results may not be predictive of future trial results, and other risks, which risks may be compounded by the ongoing COVID-19 pandemic. A further list and description of these risks, uncertainties and other risks can be found in VBL's regulatory filings with the U.S. Securities and Exchange Commission, including in its annual report on Form 20-F for the year ended December 31, 2020, and subsequent filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

    CONTACT:

    Daniel Ferry

    LifeSci Advisors

    +1 (617) 430-7576

    [email protected]



    VASCULAR BIOGENICS LTD.

    CONSOLIDATED BALANCE SHEETS

         
     December 31 
     2021 2020 
     U.S. dollars in thousands 
    ASSETS       
    Current assets:       
    Cash and cash equivalents$21,986  $13,184 
    Restricted bank deposits -   151 
    Short-term bank deposits 31,164   17,110 
    Trade receivables -   129 
    Other current assets 1,697   1,419 
    Total current assets 54,847   31,993 
            
    Non-current assets:       
    Restricted bank deposits$362  $362 
    Long-term prepaid expenses 182   241 
    Funds in respect of employee rights upon retirement 415   354 
    Property, plant and equipment, net 6,847   6,632 
    Operating lease right-of-use assets 2,008   2,124 
    Total non-current assets 9,814   9,713 
    Total assets$64,661  $41,706 
            
    LIABILITIES AND SHAREHOLDERS' EQUITY       
    Current liabilities:       
    Accounts payable:       
    Trade$4,331  $1,960 
    Other 4,408   4,275 
    Deferred revenue 658   725 
    Current maturity of operating leases 529   393 
    Current maturity of finance lease liability -   106 
    Total current liabilities$9,926  $7,459 
            
    Non-current liabilities:       
    Liability for employee rights upon retirement 546   474 
    Deferred revenue -   704 
    Operating lease liability 1,823   2,029 
    Other non-current liability 188   123 
    Total non-current liabilities 2,557   3,330 
            
    Commitments (Note 8)       
            
    Total liabilities$12,483  $10,789 
            
    Ordinary shares subject to possible redemption, 615,366 shares at redemption value (Note 9) 1,598   - 
            
    Shareholders' equity:       
    Ordinary shares, NIS 0.01 par value; Authorized as of December 31, 2021 and 2020, 150,000,000 and 70,000,000 shares, respectively; issued and outstanding as of December 31, 2021 and 2020, 68,711,584 and 48,187,463 shares, respectively (excluding 615,366 and -0- shares subject to possible redemption, as of December 31, 2021 and December 31, 2020, respectively) 171   108 
    Additional paid in capital 309,355   252,561 
    Warrants 3,127   10,401 
    Accumulated deficit (262,073)  (232,153)
    Total equity 50,580   30,917 
    Total liabilities and equity$64,661  $41,706 
            
            



    VASCULAR BIOGENICS LTD.

    CONSOLIDATED STATEMENTS OF NET LOSS AND COMPREHENSIVE LOSS

    (U.S. dollars in thousands, except share and per share amounts)

       
     Year ended December 31 
     2021  2020  2019 
     U.S. dollars in thousands 
    Revenues$768  $922  $562 
    Cost of revenues (365)  (394)  (222)
    Gross profit 403   528   340 
                
    Research and development expenses, net 22,695   19,656   14,714 
    General and administrative expenses 7,704   5,355   5,708 
    Operating loss 29,996   24,483   20,082 
                
    Financial income (120)  (363)  (870)
    Financial expenses 44   105   184 
    Financial income, net (76)  (258)  (686)
                
    Net loss and comprehensive loss$29,920  $24,225  $19,396 



       
     U.S. dollars 
    Loss per ordinary share           
    Basic and diluted$0.45  $0.55  $0.54 
                
     Number of shares

     
    Weighted average ordinary shares outstanding           
    Basic and diluted 66,346,506   43,668,155   35,881,256 





    Primary Logo

    Get the next $VBLT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VBLT

    DatePrice TargetRatingAnalyst
    7/20/2022Outperform → Perform
    Oppenheimer
    7/20/2022Buy → Neutral
    H.C. Wainwright
    7/18/2022$5.50Outperform
    Oppenheimer
    4/28/2022$5.00Buy
    Chardan Capital Markets
    More analyst ratings

    $VBLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Vascular Biogenics Ltd. (Amendment)

      SC 13G/A - Notable Labs, Ltd. (0001603207) (Subject)

      1/11/24 5:22:04 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Vascular Biogenics Ltd.

      SC 13D - Notable Labs, Ltd. (0001603207) (Subject)

      10/19/23 1:34:02 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Vascular Biogenics Ltd.

      SC 13G - Vascular Biogenics Ltd. (0001603207) (Subject)

      2/1/22 4:20:25 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBLT
    Leadership Updates

    Live Leadership Updates

    See more
    • Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors

      JERUSALEM, March 21, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (NASDAQ:DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the appointment of Ms. Ruth (Ruti) Alon to its Board of Directors, effective immediately. "We are pleased to welcome Ruti as the newest member of our Board of Directors," said Uzi Sofer, Chief Executive Officer and Chairman of Alpha Tau. "Ruti's extensive knowledge and experience advising healthcare companies through financial and strategic operations will be a tremendous asset to the Company. We are eager to have her on board and benefit from her insights into our corporate and clinical plan as we grow the Company." Ruti

      3/21/22 4:05:00 PM ET
      $DRTS
      $MACA
      $VBLT
      Medical/Dental Instruments
      Health Care
      Blank Checks
      Finance
    • VBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial Officer

      CCO appointment positions VBL to advance and accelerate commercialization strategy for ofra-vec (VB-111) Enrollment in the OVAL Study, a 400 patient Phase 3 registration-enabling trial in ovarian cancer, expected to be completed this quarter; PFS co-primary endpoint readout expected in 2H22 has potential to support BLA filing TEL AVIV, Israel and NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced the appointment of Matthew Trudeau to the newly created position of Chief Comm

      1/18/22 8:00:00 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States

      TEL AVIV, Israel and NEW YORK, Oct. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today announced the appointment of Sam Backenroth as chief financial officer (CFO) effective immediately. Mr. Backenroth is an accomplished corporate finance veteran with demonstrated success in building and financing private and public biotechnology companies. In connection with the appointment, VBL established U.S. operations in New York, which will be managed by Mr. Backenroth, and he will be responsible for leading the company's future financing and business development activities to support the company's growth initiatives. Mr. Backenroth succeeds Mr. Amos Ron, who is retiring but will cont

      10/5/21 8:00:00 AM ET
      $NBSE
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBLT
    SEC Filings

    See more

    $VBLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $VBLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form DEF 14A filed by Vascular Biogenics Ltd.

      DEF 14A - Notable Labs, Ltd. (0001603207) (Filer)

      2/16/24 9:00:13 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Vascular Biogenics Ltd.

      PRE 14A - Notable Labs, Ltd. (0001603207) (Filer)

      2/5/24 5:00:08 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vascular Biogenics Ltd. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Notable Labs, Ltd. (0001603207) (Filer)

      2/2/24 4:05:36 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Feinberg Peter

      4 - Notable Labs, Ltd. (0001603207) (Issuer)

      1/26/24 11:05:45 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Patsi Tuomo

      4 - Notable Labs, Ltd. (0001603207) (Issuer)

      1/26/24 11:05:20 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Galen Michele

      4 - Notable Labs, Ltd. (0001603207) (Issuer)

      1/26/24 11:04:43 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vascular Biogenics downgraded by Oppenheimer

      Oppenheimer downgraded Vascular Biogenics from Outperform to Perform

      7/20/22 9:01:50 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vascular Biogenics downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Vascular Biogenics from Buy to Neutral

      7/20/22 7:39:29 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer resumed coverage on Vascular Biogenics with a new price target

      Oppenheimer resumed coverage of Vascular Biogenics with a rating of Outperform and set a new price target of $5.50

      7/18/22 9:22:46 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBLT
    Financials

    Live finance-specific insights

    See more
    • Notable Labs Closes Merger Transaction With VBL Therapeutics

      - Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol "NTBL" effective at market open on October 17 - - Aggregate net transaction proceeds expected to fund planned operations into 2025 - - Completed previously announced $10.3 million private placement with leading healthtech-focused investors, led by Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund - - Predictive Precision Medicines Platform ("PPMP") applied to select and develop two clinical-stage therapeutic candidates with lead programs in acute myeloid leukemia ("AML"); four Phase 2 milestones expected by 1Q 2025 including Phase 2a results for lead asset Volasertib in

      10/16/23 1:01:41 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement

      Merger will create Nasdaq-listed, clinical-stage therapeutic platform company developing new precision medicines for patient populations selected through Notable's proprietary Predictive Precision Medicines Platform ("PPMP") Notable's validated PPMP combines multi-dimensional biological assays and machine learning to bio-simulate a patient's cancer treatment and predict their clinical response to the actual treatment Notable has applied its PPMP to selecting and developing two clinical-stage therapeutic candidates in acute myeloid leukemia ("AML"); Phase 2a results for lead asset Volasertib in adult AML in platform-predicted responding patients expected in 3Q 2024 Leading healthtech-focus

      2/23/23 7:00:00 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

      OVAL Phase 3 top-line data expected in 2H 2022; with positive results, VBL anticipates submitting a BLA to the FDA in 1H 2023 Conference Call and Webcast at 8:30 a.m. ET Today TEL AVIV, Israel and NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced financial results for the first quarter ended March 31, 2022, and provided a corporate update. "We continue to execute on our development and strategic objectives, which we believe have positioned us for a potentia

      5/17/22 7:00:00 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBLT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Notable Labs Closes Merger Transaction With VBL Therapeutics

      - Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol "NTBL" effective at market open on October 17 - - Aggregate net transaction proceeds expected to fund planned operations into 2025 - - Completed previously announced $10.3 million private placement with leading healthtech-focused investors, led by Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund - - Predictive Precision Medicines Platform ("PPMP") applied to select and develop two clinical-stage therapeutic candidates with lead programs in acute myeloid leukemia ("AML"); four Phase 2 milestones expected by 1Q 2025 including Phase 2a results for lead asset Volasertib in

      10/16/23 1:01:41 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting

      Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions MODI'IN, Israel and NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) ("VBL"), today announced that its shareholders voted to approve the previously announced proposed merger (the "Merger") with Notable Labs, Inc. ("Notable"), at the annual and special meeting (the "Meeting") which took place today, October 12, 2023. Over 98% of the votes cast at the Meeting were cast in favor of the approval of the Merger. VBL's shareholders also voted t

      10/12/23 9:00:00 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting

      MODI'IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) ("VBL"), reminds its shareholders to vote in favor of the previously announced proposed merger (the "Merger") with Notable Labs ("Notable") at the annual and special meeting (the "Meeting") for shareholders of record as of September 5, 2023. All VBL shareholders, regardless of number of ordinary shares, nominal value of NIS 0.01 ("VBL Ordinary Shares") held, are encouraged to vote "FOR" the Merger and related proposals described in the definitive proxy statement/prospectus/information statement previously filed by VBL with the U.S. Securities and Exchange Commission (the "SEC") in connection with

      10/4/23 8:00:00 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care